Abstract
Objective: To identify and describe the various economic evaluation studies in Malaysia and to determine the range of incremental cost-effectiveness ratios (ICERs) as reported in these studies. Methods: A comprehensive search of the scientific electronic databases was conducted (Medline, EBM Reviews, Embase, and hand search) to identify all published economic evaluation studies related to Malaysian healthcare. Two researchers assessed the quality of selected studies using the Critical Appraisal Skills Programme (CASP) checklist and Quality of Health Economic Studies instrument. The assessment was also reviewed by expert members of the Technical Advisory Committee of Health Technology Economic Evaluations (TACHTEE). Results: A total of 64 full-text articles were assessed for eligibility and included in this systematic review. Thirty studies were partial economic evaluations; the full economic evaluations included 17 cost-effectiveness analyses and 17 cost-utility analyses. From all the reported ICERs, the majority (68%) were categorized as highly cost-effective (ICER of less than 1 gross domestic product (GDP) per capita per quality-adjusted life-years or disability-adjusted life-years gained). Conclusion: This review identifies information gaps and loopholes in health economics research in Malaysia. Additionally, this study provides the information that the majority of published interventions in Malaysia fell within the cost-effectiveness threshold of 1 GDP per capita per quality-adjusted life-years or disability-adjusted life-years gained.
| Original language | English |
|---|---|
| Pages (from-to) | 91-99 |
| Number of pages | 9 |
| Journal | Value in Health Regional Issues |
| Volume | 21 |
| DOIs | |
| Publication status | Published - May 2020 |
Fingerprint
Keywords
- cost-effectiveness analysis
- cost-effectiveness threshold
- economic evaluations
ASJC Scopus subject areas
- Economics, Econometrics and Finance (miscellaneous)
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Health Policy
Cite this
From Evidence to Policy : Economic Evaluations of Healthcare in Malaysia - A Systematic Review. / Ku Abd Rahim, Ku Nurhasni; Kamaruzaman, Hanin Farhana; Dahlui, Maznah; Wan Puteh, Sharifa Ezat.
In: Value in Health Regional Issues, Vol. 21, 05.2020, p. 91-99.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - From Evidence to Policy
T2 - Economic Evaluations of Healthcare in Malaysia - A Systematic Review
AU - Ku Abd Rahim, Ku Nurhasni
AU - Kamaruzaman, Hanin Farhana
AU - Dahlui, Maznah
AU - Wan Puteh, Sharifa Ezat
PY - 2020/5
Y1 - 2020/5
N2 - Objective: To identify and describe the various economic evaluation studies in Malaysia and to determine the range of incremental cost-effectiveness ratios (ICERs) as reported in these studies. Methods: A comprehensive search of the scientific electronic databases was conducted (Medline, EBM Reviews, Embase, and hand search) to identify all published economic evaluation studies related to Malaysian healthcare. Two researchers assessed the quality of selected studies using the Critical Appraisal Skills Programme (CASP) checklist and Quality of Health Economic Studies instrument. The assessment was also reviewed by expert members of the Technical Advisory Committee of Health Technology Economic Evaluations (TACHTEE). Results: A total of 64 full-text articles were assessed for eligibility and included in this systematic review. Thirty studies were partial economic evaluations; the full economic evaluations included 17 cost-effectiveness analyses and 17 cost-utility analyses. From all the reported ICERs, the majority (68%) were categorized as highly cost-effective (ICER of less than 1 gross domestic product (GDP) per capita per quality-adjusted life-years or disability-adjusted life-years gained). Conclusion: This review identifies information gaps and loopholes in health economics research in Malaysia. Additionally, this study provides the information that the majority of published interventions in Malaysia fell within the cost-effectiveness threshold of 1 GDP per capita per quality-adjusted life-years or disability-adjusted life-years gained.
AB - Objective: To identify and describe the various economic evaluation studies in Malaysia and to determine the range of incremental cost-effectiveness ratios (ICERs) as reported in these studies. Methods: A comprehensive search of the scientific electronic databases was conducted (Medline, EBM Reviews, Embase, and hand search) to identify all published economic evaluation studies related to Malaysian healthcare. Two researchers assessed the quality of selected studies using the Critical Appraisal Skills Programme (CASP) checklist and Quality of Health Economic Studies instrument. The assessment was also reviewed by expert members of the Technical Advisory Committee of Health Technology Economic Evaluations (TACHTEE). Results: A total of 64 full-text articles were assessed for eligibility and included in this systematic review. Thirty studies were partial economic evaluations; the full economic evaluations included 17 cost-effectiveness analyses and 17 cost-utility analyses. From all the reported ICERs, the majority (68%) were categorized as highly cost-effective (ICER of less than 1 gross domestic product (GDP) per capita per quality-adjusted life-years or disability-adjusted life-years gained). Conclusion: This review identifies information gaps and loopholes in health economics research in Malaysia. Additionally, this study provides the information that the majority of published interventions in Malaysia fell within the cost-effectiveness threshold of 1 GDP per capita per quality-adjusted life-years or disability-adjusted life-years gained.
KW - cost-effectiveness analysis
KW - cost-effectiveness threshold
KW - economic evaluations
UR - http://www.scopus.com/inward/record.url?scp=85074369745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074369745&partnerID=8YFLogxK
U2 - 10.1016/j.vhri.2019.09.002
DO - 10.1016/j.vhri.2019.09.002
M3 - Article
C2 - 31698173
AN - SCOPUS:85074369745
VL - 21
SP - 91
EP - 99
JO - Value in Health Regional Issues
JF - Value in Health Regional Issues
SN - 2212-1099
ER -